These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Liver transplantation for patients with hepatitis B virus-related diseases. Huang J; He X; Zhu X; Chen G Zhonghua Wai Ke Za Zhi; 2001 Oct; 39(10):737-41. PubMed ID: 16201183 [TBL] [Abstract][Full Text] [Related]
30. Temporary heterotopic auxiliary liver transplantation for fulminant hepatitis B. van Hoek B; Ringers J; Kroes AC; van Krieken JH; van Schelven WD; Masclee AA; van Krikken-Hogenberk LG; Haak HR; Lamers CB; Terpstra OT J Hepatol; 1995 Aug; 23(2):109-18. PubMed ID: 7499780 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation. Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648 [TBL] [Abstract][Full Text] [Related]
32. Fulminant hepatic failure in a renal transplant recipient with positive hepatitis B surface antigens: a case report of fibrosing cholestatic hepatitis. Hung YB; Liang JT; Chu JS; Chen KM; Lee CS Hepatogastroenterology; 1995; 42(6):913-8. PubMed ID: 8847045 [TBL] [Abstract][Full Text] [Related]
33. Fulminant hepatitis B virus: recurrence after liver transplantation in two patients also infected with hepatitis delta virus. Marsman WA; Wiesner RH; Batts KP; Poterucha JJ; Porayko MK; Niesters HG; Zondervan PE; Krom RA Hepatology; 1997 Feb; 25(2):434-8. PubMed ID: 9021960 [TBL] [Abstract][Full Text] [Related]
35. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Yu JW; Sun LJ; Yan BZ; Kang P; Zhao YH Liver Int; 2011 Apr; 31(4):499-506. PubMed ID: 21382160 [TBL] [Abstract][Full Text] [Related]
36. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients]. Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179 [TBL] [Abstract][Full Text] [Related]
37. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Takaki A; Yagi T; Iwasaki Y; Sadamori H; Matsukawa H; Matsuda H; Shinoura S; Umeda Y; Miyake Y; Terada R; Kobashi H; Sakaguchi K; Tanaka N; Shiratori Y Transplantation; 2007 Jan; 83(2):231-3. PubMed ID: 17264822 [TBL] [Abstract][Full Text] [Related]
38. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts. Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887 [TBL] [Abstract][Full Text] [Related]
39. Prevention of hepatitis B virus recurrence after living donor liver transplantation. Ali H; Egawa H; Uryuhara K; Ogawa K; Kasahara M; Ueda M; Marusawa H; Nabeshima M; Tanaka K Transplant Proc; 2004 Nov; 36(9):2764-7. PubMed ID: 15621143 [TBL] [Abstract][Full Text] [Related]
40. Total hepatectomy and liver transplantation as a two-stage procedure in fulminant hepatic failure. Thompson SC Med J Aust; 1995 Jan; 162(2):110-1. PubMed ID: 7838022 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]